Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PharmAbcine, Inc.
Listed Korean bioventures are increasingly opting for rights offerings in a high interest rate environment, while unlisted firms are turning more to smaller-scale VC financings.
With Korea accounting for the second-highest number of attendees after the US this year, the BIO International Convention was crowded with biopharma firms from the country looking for partnerships. PharmAbcine CEO Jin-San Yoo shared his experience of the event and provides updates on key R&D programs including a unique TIE2 agonist antibody.
Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.
Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.
- Large Molecule
- Other Names / Subsidiaries
- PharmAbcine Australia Pty. Ltd.
- Wincal Biopharm, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.